[EN] 4-PIPERAZINYL BENZENESULFONYL INDOLES WITH 5-HT6 RECEPTOR AFFINITY [FR] INDOLES 4-PIPERAZINYLE BENZENESULFONYLE PRESENTANT UNE AFFINITE POUR LE RECEPTEUR 5-HT6
[EN] 4-PIPERAZINYL BENZENESULFONYL INDOLES WITH 5-HT6 RECEPTOR AFFINITY [FR] INDOLES 4-PIPERAZINYLE BENZENESULFONYLE PRESENTANT UNE AFFINITE POUR LE RECEPTEUR 5-HT6
4-Piperazinyl benzenesulfonyl indoles and uses thereof
申请人:——
公开号:US20040087593A1
公开(公告)日:2004-05-06
This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula I:
1
wherein R
1
, R
2
, R
3
, R
4
, and R
5
are as defined herein; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
4-piperazinyl benzenesulfonyl indoles and uses thereof
申请人:Roche Palo Alto LLC
公开号:US07022708B2
公开(公告)日:2006-04-04
This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula I:
wherein R1, R2, R3, R4, and R5 are as defined herein; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
4-PIPERAZINYL BENZENESULFONYL INDOLES WITH 5-HT6 RECEPTOR AFFINITY
申请人:F. HOFFMANN-LA ROCHE AG
公开号:EP1556037B1
公开(公告)日:2006-11-02
US7022708B2
申请人:——
公开号:US7022708B2
公开(公告)日:2006-04-04
[EN] 4-PIPERAZINYL BENZENESULFONYL INDOLES WITH 5-HT6 RECEPTOR AFFINITY<br/>[FR] INDOLES 4-PIPERAZINYLE BENZENESULFONYLE PRESENTANT UNE AFFINITE POUR LE RECEPTEUR 5-HT6
申请人:HOFFMANN LA ROCHE
公开号:WO2004035047A1
公开(公告)日:2004-04-29
This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula (I): wherein R1, R2, R3, R4, and R5 are as defined herein; or individual isomer, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.